Published online Mar 25, 2025. doi: 10.5501/wjv.v14.i1.100160
Revised: September 24, 2024
Accepted: October 15, 2024
Published online: March 25, 2025
Processing time: 111 Days and 16.2 Hours
Rhabdomyolysis is a severe condition characterized by the breakdown of muscle tissue leading to the release of intracellular components into the bloodstream. This condition, when associated with acute kidney injury (AKI), can result in signi
Core Tip: Rhabdomyolysis is a significant complication in coronavirus disease 2019 (COVID-19) patients, leading to severe acute kidney injury (AKI) with high mortality rates. This editorial highlight a study that found higher inflammatory markers and worse outcomes in patients with rhabdomyolysis-related AKI compared to other causes of AKI. Early detection and appropriate management are crucial to mitigate the adverse effects of this condition in the context of COVID-19.
- Citation: Sarker MS. Rhabdomyolysis-related acute kidney injury in COVID-19: A critical concern. World J Virol 2025; 14(1): 100160
- URL: https://www.wjgnet.com/2220-3249/full/v14/i1/100160.htm
- DOI: https://dx.doi.org/10.5501/wjv.v14.i1.100160
Rhabdomyolysis, a syndrome resulting from the breakdown of muscle fibers with the release of muscle cell contents into the bloodstream, can cause life-threatening complications such as acute kidney injury (AKI). In the context of coronavirus disease 2019 (COVID-19), rhabdomyolysis has emerged as a critical concern due to its potential to exacerbate the already complex clinical presentations associated with the virus. This editorial explores the findings of a study conducted on COVID-19 patients who developed rhabdomyolysis-related AKI and discusses the implications for clinical practice[1-3].
The study[1] in question involved 115 COVID-19 patients who developed AKI, 15 of whom were diagnosed with rhabdomyolysis. These patients were found to have significantly higher levels of inflammatory markers, including C-reactive protein (CRP), procalcitonin, and ferritin, compared to those with AKI from other causes. The elevated inflammatory response likely reflects the severity of rhabdomyolysis in the setting of COVID-19 and its contribution to the overall disease burden[4].
Patients with rhabdomyolysis-related AKI had markedly worse clinical outcomes, with a mortality rate of 73.3%, significantly higher than the 18.1% observed in patients with AKI due to other causes[1]. This stark contrast underscores the need for heightened clinical awareness and proactive management strategies for rhabdomyolysis in COVID-19 patients[5].
The findings from this study[1] suggest that early identification and aggressive management of rhabdomyolysis in COVID-19 patients could be pivotal in improving outcomes. Monitoring markers such as creatine kinase, CRP, and ferritin should be an integral part of the management protocol for COVID-19 patients at risk of rhabdomyolysis[6].
Rhabdomyolysis complicates the clinical course of COVID-19 and significantly increases the risk of mortality in patients who develop AKI. This editorial emphasizes the need for clinicians to be vigilant in recognizing and managing this condition to mitigate its impact on patient outcomes[7].
1. | Murt A, Altiparmak MR. Rhabdomyolysis-related acute kidney injury in patients with COVID-19. World J Virol. 2024;13:91107. [PubMed] [DOI] [Cited in This Article: ] |
2. | Giannoglou GD, Chatzizisis YS, Misirli G. The syndrome of rhabdomyolysis: Pathophysiology and diagnosis. Eur J Intern Med. 2007;18:90-100. [PubMed] [DOI] [Cited in This Article: ] |
3. | Bagley WH, Yang H, Shah KH. Rhabdomyolysis. Intern Emerg Med. 2007;2:210-218. [PubMed] [DOI] [Cited in This Article: ] |
4. | Haroun MW, Dieiev V, Kang J, Barbi M, Marashi Nia SF, Gabr M, Eman G, Kajita G, Swedish K. Rhabdomyolysis in COVID-19 Patients: A Retrospective Observational Study. Cureus. 2021;13:e12552. [PubMed] [DOI] [Cited in This Article: ] |
5. | Nadim MK, Forni LG, Mehta RL, Connor MJ Jr, Liu KD, Ostermann M, Rimmelé T, Zarbock A, Bell S, Bihorac A, Cantaluppi V, Hoste E, Husain-Syed F, Germain MJ, Goldstein SL, Gupta S, Joannidis M, Kashani K, Koyner JL, Legrand M, Lumlertgul N, Mohan S, Pannu N, Peng Z, Perez-Fernandez XL, Pickkers P, Prowle J, Reis T, Srisawat N, Tolwani A, Vijayan A, Villa G, Yang L, Ronco C, Kellum JA. COVID-19-associated acute kidney injury: consensus report of the 25th Acute Disease Quality Initiative (ADQI) Workgroup. Nat Rev Nephrol. 2020;16:747-764. [PubMed] [DOI] [Cited in This Article: ] |
6. | Mohamed MMB, Lukitsch I, Torres-Ortiz AE, Walker JB, Varghese V, Hernandez-Arroyo CF, Alqudsi M, LeDoux JR, Velez JCQ. Acute Kidney Injury Associated with Coronavirus Disease 2019 in Urban New Orleans. Kidney360. 2020;1:614-622. [PubMed] [DOI] [Cited in This Article: ] |
7. | Hirsch JS, Ng JH, Ross DW, Sharma P, Shah HH, Barnett RL, Hazzan AD, Fishbane S, Jhaveri KD; Northwell COVID-19 Research Consortium; Northwell Nephrology COVID-19 Research Consortium. Acute kidney injury in patients hospitalized with COVID-19. Kidney Int. 2020;98:209-218. [PubMed] [DOI] [Cited in This Article: ] |